Effects of the novel angiotensin II receptor type I antagonist, fimasartan on myocardial ischemia/reperfusion injury-Reference-Cited by-同舟云学术

Effects of the novel angiotensin II receptor type I antagonist, fimasartan on myocardial ischemia/reperfusion injury

Published:2013-10 Issue:3 Volume:168 Page:2851-2859
ISSN:0167-5273
Container-title:International Journal of Cardiology
language:en
Short-container-title:International Journal of Cardiology

Author:

Han Jin,Park Sung-Ji,Thu Vu Thi,Lee Sung-Ryul,Long Le Thanh,Kim Hyoung Kyu,Kim Nari,Park Seung Woo,Jeon Eun-Seok,Kim Eun-Ji,Yoon Chang-Hwan,Cho Goo-Young,Choi Dong-Ju

Publisher

Elsevier BV

Subject

Cardiology and Cardiovascular Medicine

Reference42 articles.

1. Effectiveness of intravenous thrombolytic treatment in acute myocardial infarction;Gruppo Italiano per lo Studio della Streptochinasi nell'Infarto Miocardico (GISSI);Lancet,1986

2. Relationship of symptom-onset-to-balloon time and door-to-balloon time with mortality in patients undergoing angioplasty for acute myocardial infarction;Cannon;JAMA,2000

3. Myocardial reperfusion injury: experimental evidence and clinical relevance;Hansen;Eur Heart J,1995

4. Inhibition of mitochondrial permeability transition pore opening: translation to patients;Gomez;Cardiovasc Res,2009

5. Mitochondrial control of cell death;Kroemer;Nat Med,2000

Cited by 28 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Targeting the mitochondrial Ca²⁺ uniporter complex in cardiovascular disease;Acta Physiologica;2023-02-24

2. Comparison Between Fimasartan Versus Other Angiotensin Receptor Blockers in Patients With Heart Failure After Acute Myocardial Infarction;Journal of Korean Medical Science;2023

3. Fimasartan ameliorates renal ischemia reperfusion injury via modulation of oxidative stress, inflammatory and apoptotic cascades in a rat model;Journal of Medicine and Life;2022-02

4. Fimasartan, an angiotensin II receptor antagonist, ameliorates an in vivo zebrafish model of heart failure;The Korean Journal of Internal Medicine;2020-11-01

5. Tetrahydrobiopterin in energy metabolism and metabolic diseases;Pharmacological Research;2020-07